MedPath

EPINASTINE HYDROCHLORIDE

These highlights do not include all the information needed to use EPINASTINE HCl safely and effectively. See full prescribing information for EPINASTINE HCl. EPINASTINE HCl Ophthalmic Solution 0.05% Initial U.S. Approval: 2003

Approved
Approval ID

0d4ee45c-e58f-4b7c-b389-898f5c27f54d

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Nov 9, 2023

Manufacturers
FDA

Somerset Therapeutics, LLC

DUNS: 079947873

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

EPINASTINE HYDROCHLORIDE

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code70069-008
Application NumberANDA090951
Product Classification
M
Marketing Category
C73584
G
Generic Name
EPINASTINE HYDROCHLORIDE
Product Specifications
Route of AdministrationOPHTHALMIC
Effective DateNovember 9, 2023
FDA Product Classification

INGREDIENTS (8)

EPINASTINE HYDROCHLORIDEActive
Quantity: 0.5 mg in 1 mL
Code: GFM415S5XL
Classification: ACTIB
BENZALKONIUM CHLORIDEInactive
Quantity: 0.1 mg in 1 mL
Code: F5UM2KM3W7
Classification: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
EDETATE DISODIUMInactive
Code: 7FLD91C86K
Classification: IACT
SODIUM PHOSPHATE, MONOBASICInactive
Code: 3980JIH2SW
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

EPINASTINE HYDROCHLORIDE - FDA Drug Approval Details